SGMO

Sangamo Therapeutics Inc

0.51

0.14+38.88%

Opening14:10 01/29 EST

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE0.4110/0.3639

TODAY RANGE0.4000-0.5150

VOL27.32M

MARKET CAP170.06M

52 WEEK RANGE0.3552-1.400

AVG VOL (3M)6.00M

% TURNOVER8.12%

TURNOVER--

P/E (TTM)-1.1414

% RANGE31.60%

EPS(TTM)-0.4428

P/E(FORWARD)-1.4440

P/B26.05

BVPS0.0194

DIVIDEND--

P/S1.861

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP166.21M

SHARES OUTSTANDING336.49M

NEXT EARNINGS03/16-03/20

FREE FLOAT328.88M

LOT SIZE1

EX-DATE--

News

Press Releases

Financial Reports

Profile

TipRanks·01/05 11:56
Sangamo Biosciences (SGMO) Receives a Hold from Wells Fargo
TipRanks·12/18/2025 13:16
Sangamo initiates rolling submission of BLA to U.S. FDA for ST-920
Reuters·12/18/2025 13:05
Sangamo Therapeutics Begins FDA Rolling Submission for ST-920 Gene Therapy in Fabry Disease
Reuters·12/18/2025 13:05
SANGAMO THERAPEUTICS INC - EXPECTS TO COMPLETE BLA SUBMISSION BY Q2 2026
Seeking Alpha·12/08/2025 19:46
Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?
Reuters·12/02/2025 18:49
BUZZ-U.S. STOCKS ON THE MOVE-CrowdStrike Holdings, Procter & Gamble, Ford Motor
Reuters·12/02/2025 15:54
BUZZ-U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Cloudflare, Boeing
Reuters·12/02/2025 14:41
BUZZ-Sangamo jumps as US FDA fast-tracks drug for chronic nerve pain
Seeking Alpha·12/02/2025 14:16
Sangamo rises as FDA grants Fast Track status to neuropathic pain asset
TipRanks·12/02/2025 13:27
Sangamo receives U.S. FDA Fast Track Designation to ST-503
Reuters·12/02/2025 13:05
SANGAMO THERAPEUTICS INC - EXPECTS TO DOSE FIRST PHASE 1/2 STAND STUDY PATIENT IN THE COMING MONTHS
Reuters·12/02/2025 13:05
SANGAMO THERAPEUTICS RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR ST-503 FOR THE TREATMENT OF SMALL FIBER NEUROPATHY
Reuters·11/26/2025 21:05
Vera Therapeutics Appoints James R. Meyers to Board of Directors
TipRanks·11/21/2025 17:05
Midday Fly By: Bitcoin slides, Lilly hits $1T market cap
TipRanks·11/21/2025 14:35
Buy Rating for Sangamo Biosciences Driven by FDA Milestone and Promising Trial Results for ST-920 Gene Therapy

Same Industry

Name/Symbol

Change%

Price

Sangamo Therapeutics Inc

SGMO

+38.88%

0.5054

Regeneron Pharmaceuticals

REGN

-0.51%

747.30

GridAI Tech

GRDX

-0.50%

2.99

BIONTECH

BNTX

+0.70%

116.98

United Therapeutics Corp.

UTHR

-0.03%

467.17

Vertex Pharmaceuticals Inc

VRTX

-0.67%

474.70

Siga Technologie

SIGA

+0.37%

6.70

Moderna

MRNA

+2.66%

46.50

Charles Riv Labs Intl Inc

CRL

-1.51%

213.60

Medpace Holdings

MEDP

-1.50%

588.95

Talphera Inc

TLPH

0.00%

0.9899

ICON PLC

ICLR

-1.97%

182.65

China Biologic

CBPO

0.00%

119.99

Iqvia Hldgs Inc

IQV

-1.66%

235.78

MOLECULAR PARTNERS AG

MOLN

-0.12%

4.15

Arcturus Therape

ARCT

+2.44%

7.55

Gilead Sciences Inc

GILD

-0.27%

139.35

PRA Health

PRAH

0.00%

165.21

Incyte Corp

INCY

+0.19%

101.38

Aptevo Therapeutics Inc

APVO

-9.25%

7.11

Biospecifics

BSTC

0.00%

88.53

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.